2. Academic Validation
  3. Discovery of a Novel Inhibitor of Histone Lysine-Specific Demethylase 1A (KDM1A/LSD1) as Orally Active Antitumor Agent

Discovery of a Novel Inhibitor of Histone Lysine-Specific Demethylase 1A (KDM1A/LSD1) as Orally Active Antitumor Agent

  • J Med Chem. 2016 Feb 25;59(4):1501-17. doi: 10.1021/acs.jmedchem.5b01209.
Paola Vianello 1,  Oronza A Botrugno 1,  Anna Cappa 1,  Roberto Dal Zuffo 1,  Paola Dessanti 1,  Antonello Mai 2 3,  Biagina Marrocco 2,  Andrea Mattevi 4,  Giuseppe Meroni 1,  Saverio Minucci 1 5,  Giulia Stazi 2,  Florian Thaler 1,  Paolo Trifiró 1,  Sergio Valente 2,  Manuela Villa 1,  Mario Varasi 1,  Ciro Mercurio 1 6
Affiliations

Affiliations

  • 1 Department of Experimental Oncology, Academic Drug Discovery, European Institute of Oncology , Via Adamello 16, 20139 Milan, Italy.
  • 2 Department of Drug Chemistry and Technologies, Sapienza University of Rome , P.le A. Moro 5, 00185 Rome, Italy.
  • 3 Pasteur Institute-Cenci Bolognetti Foundation, Sapienza University of Rome, P.le A. Moro 5, 00185 Rome, Italy.
  • 4 Department of Biology and Biotechnology, University of Pavia , Via Ferrata 1, 27100 Pavia, Italy.
  • 5 Department of Biosciences, University of Milan , Via Celoria, 26, 20133 Milan, Italy.
  • 6 Genextra Group, DAC s.r.l. , Via Adamello 16, 20139 Milan, Italy.
PMID: 26702542 DOI: 10.1021/acs.jmedchem.5b01209
Abstract

We report the stereoselective synthesis and biological activity of a novel series of tranylcypromine (TCPA) derivatives (14a-k, 15, 16), potent inhibitors of KDM1A. The new compounds strongly inhibit the clonogenic potential of acute leukemia cell lines. In particular three molecules (14d, 14e, and 14g) showing selectivity versus MAO A and remarkably inhibiting colony formation in THP-1 human leukemia cells, were assessed in mouse for their preliminary pharmacokinetic. 14d and 14e were further tested in vivo in a murine acute promyelocytic leukemia model, resulting 14d the most effective. Its two enantiomers were synthesized: the (1S,2R) enantiomer 15 showed higher activity than its (1R,2S) analogue 16, in both biochemical and cellular assays. Compound 15 exhibited in vivo efficacy after oral administration, determining a 62% increased survival in mouse leukemia model with evidence of KDM1A inhibition. The biological profile of compound 15 supports its further investigation as a Cancer therapeutic.

Figures
Products